Comparable stake leader
John K. Scott Jr.
SEC ownership of NAVIDEA BIOPHARMACEUTICALS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000810509.
Disclosed value leader
John K. Scott Jr.
Comparable rows
0/14
Latest evidence
27 Nov 2023
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
John K. Scott Jr.
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
27 Nov 2023
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000810509
- Issuer location
- Dublin, OH
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of NAVIDEA BIOPHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
John K. Scott Jr.
Disclosed value leader
John K. Scott Jr.
Comparable rows
0/14
Latest evidence
27 Nov 2023
3/4/5
Highest disclosed value: $2,795,405
14 rows are not safely comparable across share classes.
Showing 1-8 of 14 holder rows.
Quick read
John K. Scott Jr. has the largest disclosed position value at $2.8M.
0 of 14 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens John K. Scott Jr.'s linked filing trail.
Disclosed position value
Top 5
John K. Scott Jr.
$2.8M
Craig Dais Power
$85.7K
Jill Stefanelli Power
$82.9K
Power Dana J. Moss
$76.3K
Power Malcolm G. Witter
$14.5K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 14 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| John K. Scott Jr. |
3/4/5
Director, 10%+ Owner
|
—
mixed-class rows
|
$2,795,405
31,830,260 shares
mixed-class rows
|
— | 27 Nov 2023 |
| Craig Dais Power |
3/4/5
CHIEF FINANCIAL OFFICER
|
—
class O/S missing
|
$85,680
973,633 shares
|
— | 10 Nov 2023 |
| Jill Stefanelli Power |
3/4/5
Director
|
—
class O/S missing
|
$82,867
941,667 shares
|
— | 16 Nov 2023 |
| Power Dana J. Moss |
3/4/5
Director
|
—
class O/S missing
|
$76,267
866,667 shares
|
— | 16 Nov 2023 |
| Power Malcolm G. Witter |
3/4/5
Director
|
—
class O/S missing
|
$14,532
165,138 shares
|
— | 30 Nov 2022 |
| Power Amit Bhalla |
3/4/5
Director
|
—
class O/S missing
|
$6,320
71,818 shares
|
— | 30 Nov 2022 |
| Alexander L. Cappello |
3/4/5
Director
|
—
class O/S missing
|
$5,960
67,727 shares
|
— | 30 Nov 2022 |
| Power Michael S. Rosol |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
$5,900
67,045 shares
|
— | 09 Sep 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 06 Oct 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-14 of 14 reporting-owner rows connected to NAVIDEA BIOPHARMACEUTICALS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
14
Largest Forms 3/4/5 holder
John K. Scott Jr.
Net 12M change
$0
Latest report
27 Nov 2023
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| John K. Scott Jr. | Director, 10%+ Owner | $2,795,405 | Mixed | 27 Nov 2023 | ||
| Craig Dais Power | Chief Financial Officer | $85,680 | Mixed | 10 Nov 2023 | ||
| Jill Stefanelli Power | Director | $82,867 | Mixed | 16 Nov 2023 | ||
| Power Dana J. Moss | Director | $76,267 | Mixed | 16 Nov 2023 | ||
| Power Malcolm G. Witter | Director | $14,532 | Mixed | 30 Nov 2022 | ||
| Power Amit Bhalla | Director | $6,320 | Mixed | 30 Nov 2022 | ||
| Alexander L. Cappello | Director | $5,960 | Mixed | 30 Nov 2022 | ||
| Power Michael S. Rosol | Chief Medical Officer | $5,900 | Mixed | 09 Sep 2022 | ||
| Agnieszka Winkler | Director | $2,957 | Mixed | 15 Nov 2021 | ||
| Thomas F. Farb | Director | $2,941 | Mixed | 15 Nov 2021 | ||
| Power Joshua M. Wilson | Director | $2,640 | Mixed | 29 Nov 2022 | ||
| Sarah Kathryn Rouan | Director | $1,605 | Mixed | 30 Jun 2021 | ||
| Claudine Bruck | Director | $1,454 | Mixed | 30 Jun 2021 | ||
| Power Michel Mikhail | Chief Regulatory Officer | Mixed | 15 Nov 2021 |
Recent insider transactions for NAVIDEA BIOPHARMACEUTICALS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.